Impairment of CD8 T cell memory in DAA treated HCV/HIV co-infected patients

Impairment of CD8 T cell memory in DAA treated HCV/HIV co-infected patients

Bibliographic Details
Main Authors:	Hoffmann, M, Barnes, E, Abdou, M-T, Ring, S, Braun, DL, Flepp, M, Stoeckle, M, Conen, A, Beguelin, C, Schmid, P, Delaloye, J, Nguyen, A, Bernasconi, E, Bannan, C, Dorrell, L, Rauch, A, Boeni, J, Fehr, JS, Flatz, L
Other Authors:	Swiss HIV Cohort Study
Format:	Conference item
Language:	English
Published:	Wiley 2019

Similar Items

Virological impact of HCV elimination with DAAs in the HIV reservoir in HIV/HCV patients
by: M. Coiras, et al.
Published: (2019-12-01)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
by: Fabrizio Fabrizi, et al.
Published: (2021-04-01)

Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
by: A. Maughan, et al.
Published: (2019-05-01)

Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure
by: Mahmood Danishwar, et al.
Published: (2022-02-01)

Anti-HCV DAA are needed whatever liver fibrosis is. The cons
by: Pablo Barreiro
Published: (2016-05-01)

Treatment and re-treatment results of HCV patients in the DAA era.
by: Felix Piecha, et al.
Published: (2020-01-01)

WAITING DAAS LIST MORTALITY IMPACT IN HCV CIRRHOTIC PATIENTS
by: Giovanni Faria SILVA, et al.

Anti-HCV DAA are needed whatever liver fibrosis is. The pros
by: Albert Tran
Published: (2016-05-01)

Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
by: Julia L. Casey, et al.
Published: (2019-04-01)

Evaluation of HCV-related liver fibrosis post-successful DAA therapy
by: Nermine Ehsan, et al.
Published: (2021-06-01)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
by: Claudia Minosse, et al.
Published: (2021-06-01)

Letter to the editor: Successful eradication of HCV by short-course DAAs in HCV-Positive donor to HCV-Negative recipient during Haplo-HSCT
by: Yuh-Ching Gau, et al.
Published: (2020-11-01)

Seven gene signature explores the impact of DAAs on the appearance of hepatocellular carcinoma in HCV infected patients
by: Reham M. Dawood, et al.
Published: (2022-08-01)

HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs
by: Rujipat Wasitthankasem, et al.
Published: (2017-11-01)

Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects
by: Valeria Bono, et al.
Published: (2022-07-01)

Longitudinal assessment of HCV core antigen kinetics to monitor therapeutic response in the age of DAAs.
by: Suresh Ponnuvel, et al.
Published: (2023-01-01)

Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
by: Atsushi Hosui, et al.
Published: (2021-12-01)

CHALLENGES AND PERSPECTIVES IN HEPATITIS C VIRUS (HCV) RESEARCH IN AN ERA OF DIRECT ACTING ANTIVIRAL (DAA) THERAPY
by: A. Budkowska
Published: (2018-12-01)

Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects
by: Paola Zuccalà, et al.
Published: (2022-10-01)

Immunological and Clinical Impact of DAA-Mediated HCV Eradication in a Cohort of HIV/HCV Coinfected Patients: Monocentric Italian Experience
by: Andrea Marino, et al.
Published: (2021-12-01)

Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
by: Yu Zhang, et al.
Published: (2016-01-01)

Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort
by: d'Arminio Monforte, A, et al.
Published: (2017)

Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy
by: Piero Colombatto, et al.
Published: (2022-03-01)

Dynamics of cellular senescence markers after HCV elimination spontaneously or by DAAs in people living with HIV
by: Violeta Lara-Aguilar, et al.
Published: (2023-06-01)

Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
by: Mercedes Márquez-Coello, et al.
Published: (2021-05-01)

P22 ‘No closed door’ to HCV treatment in the era of fully funded DAAs: access to a peer navigator is essential
by: M.E. Harrod, et al.
Published: (2017-08-01)

Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy
by: Smith, DA, et al.
Published: (2021)

Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy.
by: Matthew A Burchill, et al.
Published: (2017-01-01)

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
by: Julia M Grottenthaler, et al.
Published: (2018-01-01)

Significant early and long-term improvement of neuropsychiatry symptomatology in HCV-infected patients after viral eradication with DAA
by: R. Martin-Santos, et al.
Published: (2022-06-01)

O12 Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued
by: A.J. Kwon, et al.
Published: (2017-08-01)

Access to free DAAs for people who inject drugs: is it sufficient to increase the update of HCV treatment by PWIDs?
by: Maka Gogia, et al.
Published: (2018-05-01)

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV.
by: Giulia Morsica, et al.
Published: (2022-01-01)

Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy
by: Stefania Farcomeni, et al.
Published: (2021-11-01)

Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens
by: Ghias Un Nabi Tayyab, et al.
Published: (2020-04-01)

No gender differences in the 24-month course of non-invasive liver fibrosis markers after DAA therapy in HCV-mono and HCV/HIV-coinfected patients
by: Julio Collazos, et al.
Published: (2024-03-01)

Single-cell transcriptomic analyses of T cells in chronic HCV-infected patients dominated by DAA-induced interferon signaling changes.
by: Matthew A Burchill, et al.
Published: (2021-08-01)

Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment
by: Amer F, et al.
Published: (2019-09-01)

Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection
by: Natthaya Chuaypen, et al.
Published: (2023-09-01)

Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study
by: Filomena Morisco, et al.
Published: (2021-07-01)